Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $42.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective hoisted by Stifel Nicolaus from $40.00 to $42.00 in a research report released on Wednesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other brokerages have also recently issued reports on SNDX. JPMorgan Chase & Co. restated an overweight rating and issued a $34.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. HC Wainwright restated a buy rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday, June 17th. Scotiabank lowered shares of Syndax Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, June 14th. Finally, Citigroup cut their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a buy rating for the company in a report on Thursday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $34.77.

Syndax Pharmaceuticals Stock Up 1.0 %

Syndax Pharmaceuticals stock opened at $20.53 on Wednesday. The company has a market capitalization of $1.74 billion, a P/E ratio of -6.38 and a beta of 1.01. The firm has a 50 day moving average price of $20.49 and a 200-day moving average price of $21.48. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same period in the prior year, the business earned ($0.59) EPS. Equities analysts expect that Syndax Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Activity

In related news, CFO Keith A. Goldan bought 1,250 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $20.03 per share, with a total value of $25,037.50. Following the completion of the purchase, the chief financial officer now directly owns 52,623 shares of the company’s stock, valued at approximately $1,054,038.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System increased its stake in Syndax Pharmaceuticals by 5.3% in the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock valued at $357,000 after acquiring an additional 835 shares during the last quarter. Sei Investments Co. increased its position in shares of Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock valued at $963,000 after purchasing an additional 991 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of Syndax Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after buying an additional 1,150 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Syndax Pharmaceuticals by 9.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock worth $305,000 after buying an additional 1,162 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after buying an additional 1,312 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).